Invectys Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4M
- Investors
-
9
Invectys General Information
Description
Operator of a biopharmaceutical company intended to offer an immunotherapy approach to treat cancer. The company focuses on mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients by targeting a broad-ranging cancer antigen, enabling healthcare practitioners to target telomerase in the cell and improve patients' health.
Contact Information
Website
www.invectys.comCorporate Office
- 2415 West Alabama
- Suite 220
- Houston, TX 77098
- United States
Corporate Office
- 2415 West Alabama
- Suite 220
- Houston, TX 77098
- United States
Invectys Timeline
Invectys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 10-Oct-2024 | $4M | Completed | Clinical Trials - Phase 2 | ||
| 11. Accelerator/Incubator | 26-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 10. Later Stage VC (Series B) | Completed | Clinical Trials - Phase 2 | ||||
| 9. Grant | 20-May-2020 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series A) | 29-Oct-2018 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 12-Jul-2017 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 21-Jan-2016 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 21-Jan-2016 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 30-Mar-2015 | $1.81M | $14.3M | Completed | Clinical Trials - Phase 2 | |
| 3. Early Stage VC | 30-Jul-2014 | $7.88M | $12.4M | Completed | Startup |
Invectys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 10,667 | $0.344934 | $107.79 | $107.79 | 1x | $107.79 | 3.22% | |
| Ordinary | 23,333 | $0.344934 | $68.99 | $68.99 | 1x | $68.99 | 7.04% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Invectys Comparisons
Industry
Financing
Details
Invectys Competitors (102)
One of Invectys’s 102 competitors is Iterion Therapeutics, a Venture Capital-Backed company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Iterion Therapeutics | Venture Capital-Backed | Houston, TX | ||||
| Nexoplex bio | Formerly VC-backed | Emeryville, CA | ||||
| EnGeneIC | Formerly VC-backed | Sydney, Australia | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Immune-Onc Therapeutics | Venture Capital-Backed | Palo Alto, CA |
Invectys Patents
Invectys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023402360-A1 | Humanized anti-hla-g chimeric antigen receptors and uses thereof | Pending | 28-Nov-2022 | ||
| EP-4626473-A1 | Humanized anti-hla-g chimeric antigen receptors and uses thereof | Inactive | 28-Nov-2022 | ||
| WO-2024118469-A1 | Humanized anti-hla-g chimeric antigen receptors and uses thereof | Inactive | 28-Nov-2022 | ||
| WO-2022079308-A1 | Chimeric constructs useful in vaccination and cancer therapy | Inactive | 16-Oct-2020 | ||
| JP-7627687-B2 | Single domain antibodies against lilrb2 | Active | 20-Sep-2019 | C07K16/2803 |
Invectys Signals
Invectys Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Matwin | Accelerator/Incubator | |||
| Cancer Prevention and Research Institute of Texas | Government | |||
| Golda Darty Partners | Family Office | Minority | ||
| Johnson Financial Group | Family Office | Minority | ||
| Very | Corporation | Minority |
Invectys FAQs
-
When was Invectys founded?
Invectys was founded in 2010.
-
Where is Invectys headquartered?
Invectys is headquartered in Houston, TX.
-
What is the size of Invectys?
Invectys has 19 total employees.
-
What industry is Invectys in?
Invectys’s primary industry is Drug Discovery.
-
Is Invectys a private or public company?
Invectys is a Private company.
-
What is Invectys’s current revenue?
The current revenue for Invectys is .
-
How much funding has Invectys raised over time?
Invectys has raised $83M.
-
Who are Invectys’s investors?
Matwin, Cancer Prevention and Research Institute of Texas, Golda Darty Partners, Johnson Financial Group, and Very are 5 of 9 investors who have invested in Invectys.
-
Who are Invectys’s competitors?
Iterion Therapeutics, Nexoplex bio, EnGeneIC, Renova Therapeutics, and Immune-Onc Therapeutics are some of the 102 competitors of Invectys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process